
Invivyd revenue accelerates 18% to $15.4 million
Key points
- Invivyd (NASDAQ:IVVD) reported third-quarter 2026 PEMGARDA revenue of $15.4 million, up 18% year over year.
- Net loss widened to $33.5 million from $10.5 million, while cash and cash equivalents totalled $126.4 million.
- The company expects interim Phase 3 DECLARATION results for VYD2311 imminently as it advances additional clinical programs and prepares for potential commercialization.
Invivyd (NASDAQ:IVVD) reported third-quarter 2026 PEMGARDA revenue of $15.4 million, up 18% year over year, while its net loss widened to $33.5 million.
Revenue increased from $13.1 million in the third quarter of 2025, driven primarily by higher patient demand for PEMGARDA, an antibody treatment authorized for COVID-19 prevention in certain immunocompromised patients.
Research and development expenses increased to $18.7 million from $8 million, while selling, general and administrative expenses rose to $30.3 million from $15 million, contributing to the wider quarterly loss.
The company reported positive Phase 3 LIBERTY results, with VYD2311 meeting all primary and secondary endpoints for safety and tolerability compared with an mRNA COVID-19 vaccine, while its FLINTLOCK Phase 2 trial began in October.
Invivyd held $126.4 million in cash at September 30, is preparing for potential VYD2311 commercialization and is developing its measles antibody candidate VMS063 for clinical development in 2027, while PEMGARDA's emergency use authorization is scheduled to end in June 2027.
Frequently asked questions
More from United States
Cypherpunk posts $306 million profit on derivative gain
Eloxx loss widens to $5.5 million in Q3
POET revenue skyrockets 244% to $1.03 million
Prelude Therapeutics loss narrows to $12.5 million
Blackstone Digital Trust reports $5 billion Amazon deal
Granite completes two deals targeting $175 million revenue


